💬 Help us build what families need most!
The IFOPA Family Services team is planning what comes next, and the people who know best what would help are living with FOP, caring for someone who does, or supporting a loved one 💚
Tell us:
✨ What topics matter most to you
📲 Where and how you like to find information
🌱 What new programs or support would make a real difference
Fifteen minutes of your time could shape the programs and resources families use for years to come ⏱️
📆 The survey closes December 20.
👉 Take the survey: ifopa.formstack.com/forms/if…
Every response helps guide our work, and your voice makes our programs better. Thank you! 💙 #FOPCommunity
💬 Quick question: if you could wave a magic wand and add one thing to IFOPA Family Services, what would it be?
We’re not kidding. We really want to know! 💚
Our Family Services team is putting the priorities from our recent strategic planning into action, and we need people living with FOP, caregivers, and family members to help shape the future. 🧭
Your answers will help us figure out:
✨ Which topics matter most to you
📲 How you like to get information and resources
🌱 Which new programs or support would be most valuable
Submit your responses by December 15 📆
⏱️ It takes about 15 minutes.
👉 Take the survey: ifopa.formstack.com/forms/if…
Haven’t done it yet? This is your friendly nudge! 🙌 Thank you for helping shape the future of Family Services 💙 #FOPCommunity#CaregiverSupport
👉 Reminder: Join the Peer Support Group for Adults with FOP
🗓️ Wednesday, November 11 | ⏰ 12 PM ET / 18:00 CET
A chance to connect and share facilitated by Dr. Al Freedman (@amf41), a psychologist & rare disease parent.
🔗 Register: ifopa.org/november-2026-fop-…
Participants should be comfortable speaking and understanding English. #FOPawareness#RareDisease
👉 Final Reminder: Join our October Bereaved Families Virtual Meeting on Thursday, October 22, at 8 pm ET 💙
A virtual space for those who’ve lost loved ones to FOP to support one another.
🔗 Register: ifopa.org/october-2026-fop-b…
Participants should be comfortable speaking and understanding English.
A special message from our IFOPA Executive Director Michelle Davis (@MichelleDavisKC) at @ASBMR 2026 (the American Society for Bone and Mineral Research conference) 🦴 🩻 🔬 🧬 🙌 ✨
👉 Reminder: Join the Peer Support Group for Adults with FOP
🗓️ Tuesday, October 13 | ⏰ 12 PM EDT / 18:00 CEST
A chance to connect and share facilitated by Dr. Al Freedman (@amf41), a psychologist & rare disease parent.
🔗 Register: ifopa.org/october-2026-fop-p…
Participants should be comfortable speaking and understanding English. #FOPawareness#RareDisease
Join our October Bereaved Families Virtual Meeting on Thursday, October 22, at 8 pm ET 💙
A virtual space for those who’ve lost loved ones to FOP to support one another.
🔗 Register: ifopa.org/october-2026-fop-b…
Participants should be comfortable speaking and understanding English.
New Resources: Learn More About Atebrioz™ (zilurgisertib) 💙
Following the FDA's recent approval of Atebrioz™ (zilurgisertib) to treat FOP, Mirum Pharmaceuticals (@mirumpharma) has launched two new educational resources for the community.
👉 Visit atebrioz.com to learn more about Atebrioz™ and what it may mean for people living with FOP.
If you're a member of the U.S. FOP community, an adult with FOP or have a child age 12 or older, and are interested in learning more about Atebrioz™, we also encourage you to share this healthcare provider resource with your doctor:
👉 atebriozhcp.com
This site offers detailed clinical information to help your care team better understand this treatment option and determine whether it may be right for you. As always, treatment decisions should be made in partnership with your doctor. 🩺
📌 Learn more about the FDA approval: ifopa.org/us-fda-approves-mi…
💡 Do you know what Atebrioz™ is?
It is the brand name for Mirum's (@mirumpharma) drug zilurgisertib, which was approved today in the 🇺🇸 United States.
Atebrioz is a once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP.
Atebrioz (zilurgisertib) is the third drug approved for FOP in the U.S.
As we announce this decision, we are deeply grateful to people living with FOP from around the world who participated in the Phase 2 PROGRESS trial of zilurgisertib 🙌
@Novartis originally developed zilurgisertib and then licensed it to @Incyte, which conducted the Phase 2 trial in adults and children ages 12 and up. Mirum announced they had licensed zilurgisertib in May 2026.
📌 Learn more and read Mirum’s press release: ifopa.org/zilurgisertib-fda-…
Congratulations to the FOP community on this very special day! 💚💙 #DrugDevelopment#RareDisease
👉 Reminder: Join the Peer Support Group for Adults with FOP
🗓️ Tuesday, October 13 | ⏰ 12 PM EDT / 18:00 CEST
A chance to connect and share facilitated by Dr. Al Freedman (@amf41), a psychologist & rare disease parent.
🔗 Register: ifopa.org/october-2026-fop-p…
Participants should be comfortable speaking and understanding English. #FOPawareness#RareDisease
A Mouse Model Moving FOP Research Forward 🐭🔬
Progress in FOP research depends on more than groundbreaking ideas; researchers need access to the tools and resources that turn those ideas into action.
Thanks to a generous sponsorship from La Jolla Pharmaceutical Company in 2018, the IFOPA created a FOP mouse model designed to recreate key features of the disease, including heterotopic bone formation and flare-ups. Unlike other models that can involve complex agreements and fees, the IFOPA's model is available to any researcher with a valid research plan, who pays only shipping costs. 🐭
Over the past eight years, this shared resource has been managed by Daniel Perrien, PhD, Associate Professor in the Division of Endocrinology at Emory University, and used across 13 labs, 4 countries, and 2 continents, contributing to 11 publications and helping secure 2 R01 and 1 R21 grants from the National Institutes of Health.
"Animal models recapitulating FOP phenotypes have been instrumental for elucidating disease mechanisms and developing therapeutic strategies," shares Dr. Jae Shim of UMass Chan Medical School, whose team has used the model to advance gene therapy research.
Your support of In Pursuit of a Cure makes this kind of progress possible, removing barriers and giving scientists around the world free access to critical research tools. 💙
💡 Read the full story: ifopa.org/a-mouse-model-movi…
🧬 Give to In Pursuit of a Cure today: ifopa.org/cure-fop#cureFOP#InPursuitofaCure
👉 Final Reminder: Join our September Bereaved Families Virtual Meeting on Thursday, September 10, at 8 pm EDT 💙
Led by Bereaved FOP mom Marilyn Hair (@marhair), the group is an opportunity for those who have lost a friend or loved one to FOP to come together virtually to support each other 🕯️
🔗 Register: ifopa.org/september-2026-fop…
Participants should be comfortable speaking and understanding English.